Kezar Life Sciences, Inc. (KZR)
KZR moved a median of +0.14% 30 minutes after news, and +0.68% by the close. How KZR actually reacts to news — the realized, point-in-time move the market made, measured across 192 labeled events over the last three years with zero look-ahead.
KZR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 147 |
| 30-min | +0.14% | 55% | 156 |
| 60-min | +0.34% | 58% | 156 |
| to close | +0.68% | 62% | 159 |
| Middle 50% of KZR reactions | -0.87% to +1.23% |
|---|---|
| Median reaction (30-min) | +0.14% |
| Measured reactions | 192 |
Half of all Kezar Life Sciences, Inc. news events land between -0.87% and +1.23% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How KZR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 10 | +1.29% | 70% | +3.92% |
| Rating reiterations | 31 | +0.08% | 52% | +0.14% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how KZR ranks against every other measured name →
That’s how KZR usually reacts — get an email when it moves on news →Email me when KZR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KZR's baseline. Nothing else.
Recent KZR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Kezar Life Sciences, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Kezar Life Sciences, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 10-Q Kezar Life Sciences, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Kezar Life Sciences, For: May 08 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Kezar Life Sciences, | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Kezar Life Sciences, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 10-K/A Kezar Life Sciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.55% | +0.96% | |
| Are KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.00% | +0.41% | |
| Are KZR, TALK, WBD Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.00% | +0.14% | |
| Form 8-K Kezar Life Sciences, For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.27% | |
| Are KZR, NSA, EQH, CTRA Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | — | +0.07% | |
| Form 8-K Kezar Life Sciences, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | +2.06% | |
| KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | +0.14% | +2.06% | |
| Form 10-K Kezar Life Sciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.14% | +2.06% | |
| Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences | Press release | Business Wire | +0.00% | +2.42% | |
| Form 8-K Kezar Life Sciences, For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.42% | |
| Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis | Press release | Business Wire | +1.62% | +0.16% | |
| Form 10-Q Kezar Life Sciences, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | — | |
| Form 8-K Kezar Life Sciences, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | — | |
| Kezar Life Sciences Reports Third Quarter 2025 Financial Results | Press release | Business Wire | +0.00% | — | |
| Form 8-K Kezar Life Sciences, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +1.50% | +2.82% | |
| Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 | Press release | Business Wire | +0.00% | -0.98% | |
| Form 8-K Kezar Life Sciences, For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -0.97% | |
| Form 8-K Kezar Life Sciences, For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | +4.07% | +12.37% | |
| Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives | Press release | Business Wire | +4.07% | +12.37% | |
| Kezar Life Sciences to Participate in Two Upcoming Investor Conferences | Press release | Business Wire | -1.09% | -1.00% | |
| Form 10-Q Kezar Life Sciences, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.05% | |
| Form 8-K Kezar Life Sciences, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.05% | |
| Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | Business Wire | +0.00% | +2.05% | |
| Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis | Press release | Business Wire | -3.72% | -1.53% | |
| Form 8-K Kezar Life Sciences, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +1.16% | +3.02% | |
| Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference | Press release | Business Wire | +0.49% | +3.22% | |
| Form 10-Q Kezar Life Sciences, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.90% | |
| Form 8-K Kezar Life Sciences, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.90% | |
| Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | Business Wire | +0.00% | -1.90% | |
| Form ARS Kezar Life Sciences, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | -8.26% | |
| Form DEF 14A Kezar Life Sciences, For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | — | -8.26% | |
| Form DEFA14A Kezar Life Sciences, | SEC filing · Form DEFA14A | SEC EDGAR | — | -8.26% | |
| Form 8-K Kezar Life Sciences, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | — | +2.22% | |
| Form 10-K Kezar Life Sciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.41% | -0.70% | |
| Form 8-K Kezar Life Sciences, For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | -0.70% | |
| Form S-8 Kezar Life Sciences, | SEC filing · Form S-8 | SEC EDGAR | -0.18% | -8.50% | |
| Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results | Press release | Business Wire | -1.41% | -0.70% | |
| Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 | Press release | Business Wire | -0.32% | -0.65% | |
| Form 8-K Kezar Life Sciences, For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -2.17% | -4.83% | |
| Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 | Press release | Business Wire | -0.16% | +2.77% | |
| Form EFFECT Kezar Life Sciences, | SEC filing · Form EFFECT | SEC EDGAR | +1.45% | +0.83% | |
| Form S-3 Kezar Life Sciences, | SEC filing · Form S-3 | SEC EDGAR | +1.11% | +0.95% | |
| Form 8-K Kezar Life Sciences, For: Jan 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Kezar Life Sciences, For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | -3.03% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KZR section they belong to.
Where else KZR is measured.
KZR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Apollo Medical Holdings, Inc. (AMEH) | 192 | +0.16% | 55% |
| Citius Pharmaceuticals, Inc. (CTXR) | 192 | -1.42% | 30% |
| TAKEDA PHARMA (TKPYY) | 192 | 0.00% | 47% |
| Arbutus Biopharma Corporation (ABUS) | 191 | +0.11% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Kezar Life Sciences, Inc.'s median reaction calculated?
Every labeled KZR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 192 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of KZR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KZR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.